and Healthcare Industry Group
-
- 41,400 Million
- FY2023 Revenue
-
- 2,011 Million
- FY2023 Net Profit after deducting extraordinary gain or loss attributable to owners of the parent
-
- 5,937 Million
- FY2023 R&D Expenditure
-
- 40,370
- Global Employees
-
- Five-Star (Excellence)
- 2022 Corporate Social Responsibility Report Rating
-
- A
- MSCI ESG Rating
Unit: RMB million
-
Artesun® (Artesunate for Injection)
The WHO-recommended First-line Treatment of Severe Malaria
By the end of 2022, Fosun Pharma's self-developed antimalarial innovative drug Artesun® (Artesunate for Injection) had helped more than 56 million patients with severe malaria worldwide.
-
Han Li Kang (Rituximab Injection)
First China-developed Biosimilar
Since its approval in 2019, Han Li Kang has benefited more than 100,000 patients in China
-
Han Qu You(trastuzumab, Zercepac® in the EU)
The first China-developed mAb biosimilar approved both in China and in the EU
Zercepac®（150mg）has been marketed in nearly 20 EU countries and regions such as England, Germany, Spain and France.
-
Han Si Zhuang （Serplulimab Injection）
Henlius’s first self-developed innovative monoclonal antibody approved by the NMPA
-
Yi Kai Da (Axicabtagene Ciloleucel)
China's first approved CAR-T cell therapy
As of the end of 2022, Yi Kai Da has been included in the urban customized commercial health insurance of 70 provinces and municipalities and over 60 commercial insurances, while the number of treatment centers on record ~exceeded 130. As of the end of January 2023, nearly 300 patients with relapsed or refractory large B-cell lymphoma lymphoma had been treated with Yi Kai Da.
-
Su Ke Xin (Avatrombopag Maleate Tablets)
Fosun Pharma’s first innovative small molecule drug introduced and China’s first drug approved for CLDT treatment
Su Ke Xin was included in the national medical insurance catalog in December 2020, and the medical insurance standard has been implemented from March 1, 2021, which comprehensively improves the accessibility of clinical treatment for patients
-
mRNA COVID-19 Vaccine COMIRNATY® (also known as BNT162b2)
Both the monovalent COVID-19 vaccine COMIRNATY (30 mg per dose) (also known as BNT162b2 or COMIRNATY Original) and COMIRNATY Original/Omicron BA.4/BA.5 bivalent COVID-19 vaccine (also known as COMIRNATY Bivalent COVID-19 Vaccine) were officially registered in Hong Kong SAR and approved as a regular imported vaccine by the Macao SAR., fully covering the public and private markets.
-
Novel Coronavirus (2019-nCoV) Antigen Detection Kit and Novel Coronavirus (2019-nCoV) RT-PCR Detection Kit
Fosun Diagnostics is one of the dual-certificate enterprises that have obtained the registration certificates of both Novel Coronavirus Antigen Detection Kit and Novel Coronavirus RT-PCR Detection Kit
-
Da Vinci Surgical Robots
The first robotic surgery system approved by the FDA for general laparoscopic surgery and the most widely used laparoscopic surgery robot in the world
-
-
Pharmaceutical Manufacturing
-
-
Vaccines
-
-
Medical Devices
-
-
Medical Diagnosis
-
-
Healthcare Services
-
-
Pharmaceutical Distribution And Retail
-
- 2022-09-19
Fosun Pharma and Carephar Enter into a Global Collaboration to Co-develop and Exclusively Commercialize China's First Self-Developed P-CAB Product Keverprazan Hydrochloride
(September 19, 2022, Shanghai, China)Shanghai Fosun Pharmaceutical (Group) Co., Ltd.(“Fosun Pharma”, Stock Code: 600196.SH; 02196.HK), a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China, announced that its subsidiary Shanghai Fosun Pharmaceutical Industry Development Co. Ltd.
- 2022-09-07
Neovii and Fosun Pharma Enter into an Exclusive Agreement for Development and Commercialization for Grafalon® in China
(September 7, 2022,Rapperswil,Switzerland and Shanghai, China)Neovii Pharmaceuticals AG(“Neovii”) and Shanghai Fosun Pharmaceutical Industry Development Co. Ltd(“Fosun Pharma Industry”), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- 2022-08-29
Fosun Pharma Announces 2022 Interim Results Stable Revenue Growth and Recurring Income, Elevating the Revenue Contribution of New Products, and Accelerating International Layout
(August 30, 2022, Shanghai, China) August 29, 2022,Shanghai Fosun Pharmaceutical (Group) Co., Ltd.(“Fosun Pharma” or “the Group”; Stock Code: 600196.SH, 02196.HK), a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China, announced its interim results for the first half of 2022.
-
Dual-Listed on A+H Shares
Sustainable Development
In Pursuit of Sustainable Development of Talents and Products
Fosun Pharma adheres to the concept of "pursuing sustainable development of talents and products", comprehensively practices corporate social responsibility, continuously improves the satisfaction of stakeholders, and is committed to leading the development of social responsibility in the industry.